Skip to content

Effect of Need to Void on Parkinsonian Gait

Effect of Need to Void on Parkinsonian Gait

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03314610
Enrollment
11
Registered
2017-10-19
Start date
2017-10-16
Completion date
2017-12-30
Last updated
2019-09-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lower Urinary Tract Symptoms, Parkinsonism, Gait Disorders, Neurologic

Brief summary

This study evaluates the effect of the need to void on parkinsonian gait

Detailed description

Parkinsonian syndromes are common causes of gait disorders, associated with hypometria, bradykinesia or rigidity. If motor disorders are the most visible part, lower urinary tract dysfunction is one of the most prevalent dysautonomic disorder (27-80%), especially over active bladder syndrome (OAB). If it seems evident that gait and urinary disorders are linked, because of similar anatomic pathways and control processes, no studies have investigated their association in extrapyramidal patients. The aim of this study is to assess the effect of the need to void on the walking speed in this particular population. This prospective study inclues all parkinsonian syndromes who had a follow-up for OAB. They must have a security delay over five minutes, no severe cognitive, motor or psychiatric disorders. We invite them to drink until a need to void (or equivalent). Bladder filling is measured by bladder scan, then they performe gait tests in a specific place, with calm and no passage : Patient can use their habitual walking device. Speed walk asking is comfortable for the two test. Three ten-meter tests, one double-task ten-meter test, one timed-up-and-go test, one timed raise of the floor (GMT). We repeat the same tests after voiding or self-catheterization. Toilets are just next to the hall where they realize the tests. A clinical examination assesses urinary dysfunction (USP, IPSS), motor score (UPDRS-III, Hoehn and Yahr scale, daily equivalent of levodopa), history of falls and comorbidities.

Interventions

No intervention, only propose water and wait for need to void

Sponsors

Pierre and Marie Curie University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No

Inclusion criteria

* Parkinsonian syndromes * Follow in neurourology for Lower urinary tract symptoms * Able to walk 50 meters without human assistance * able to hold voiding for more than 3 minutes

Exclusion criteria

* Actual urinary tract infection * Montreal cognitive assessment \< 20/30 * Acute psychiatric or neurologic disorders who can interfer with walking tests

Design outcomes

Primary

MeasureTime frameDescription
Gait Speed[Time Frame: 1 Day: at strong desire to void and just after void]Gait speed calculated from 10 meter walk test. Time is recorded by a manual chronometer. 3 records are done, mean time is calculated.

Secondary

MeasureTime frameDescription
Time for Timed up and Go[Time Frame: 1 Day: at strong desire to void and just after void]1 record is done for timed up and go test. Time is recorded by a manual chronometer
Time for GMT[Time Frame: 1 Day: at strong desire to void and just after void]1 record is done for GMT , time is recorded by a manual chronometer
Variation of gait speed[Time Frame: 1 Day: at strong desire to void and just after void]Standard deviation and Coefficient of variation is calculated from the 3 records of 10 meter walk test.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026